Reconsidering the Diagnosis and Management of Obinutuzumab-induced Acute Thrombocytopenia
Shinya Fujita · 2025
Read Reconsidering the Diagnosis and Management of Obinutuzumab-induced Acute Thrombocytopenia by Shinya Fujita (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13561547.txt.
Description
Shinya Fujita, a lone author, wrote a letter in 2025 that rethinks a case of sudden low platelets tied to a cancer drug. The drug, obinutuzumab, treats blood cancers, and the case team had read the drop as a self-attack on platelets. Fujita notes that no bone marrow test was done to prove platelet making was sound at the low point.
Such a test is key, he says, since low counts can stem from poor making, not just fast loss. Guide lines urge it for patients over 60 or with odd features, both met here. He also questions the care path: first-line steroids or immune globulin were skipped for a growth drug kept for chronic cases. He urges early marrow checks to match care to the true cause.
Catalog record
| CREATOR | Shinya Fujita |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 3 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |